A Phase IV, Randomized, Double-Blind, Placebo-Controlled Crossover Study of the Effects of Ustekinumab on Vascular Inflammation in Psoriasis (the VIP-U Trial)-Reference-Cited by-同舟云学术

A Phase IV, Randomized, Double-Blind, Placebo-Controlled Crossover Study of the Effects of Ustekinumab on Vascular Inflammation in Psoriasis (the VIP-U Trial)

Published:2020-01 Issue:1 Volume:140 Page:85-93.e2
ISSN:0022-202X
Container-title:Journal of Investigative Dermatology
language:en
Short-container-title:Journal of Investigative Dermatology

Author:

Gelfand Joel M.^ORCID,Shin Daniel B.^ORCID,Alavi Abass^ORCID,Torigian Drew A.^ORCID,Werner Tom^ORCID,Papadopoulos Maryte^ORCID,Takeshita Junko^ORCID,Noe Megan H.^ORCID,Dey Amit K.^ORCID,Playford Martin P.^ORCID,Mehta Nehal N.^ORCID

Funder

Trustees of the University of Pennsylvania

NIAMS

NHLBI Intramural Research Program

Publisher

Elsevier BV

Subject

Cell Biology,Dermatology,Molecular Biology,Biochemistry

Reference38 articles.

1. Gelfand JM. Gelfand JM. Psoriasis and metabolic disease: epidemiology and pathophysiology;Azfar;Curr Opin Rheumatol,2008

2. TNF-alpha antagonist and vascular inflammation in patients with psoriasis vulgaris: A randomized placebo-controlled study;Bissonnette;J Invest Dermatol,2017

3. Quantitative assessment of the atherosclerotic burden of the aorta by combined FDG-PET and CT image analysis: a new concept;Bural;Nucl Med Biol,2006